These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30931346)

  • 1. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States.
    Chahal HS; Peters MG; Harris AM; McCabe D; Volberding P; Kahn JG
    Open Forum Infect Dis; 2019 Jan; 6(1):ofy353. PubMed ID: 30931346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
    Hutton DW; Tan D; So SK; Brandeau ML
    Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW; Woo G; Jenny Heathcote E; Krahn M
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
    Mangen MJ; Stibbe H; Urbanus A; Siedenburg EC; Waldhober Q; de Wit GA; van Steenbergen JE;
    Vaccine; 2017 May; 35(24):3215-3221. PubMed ID: 28483198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.
    Rossi C; Schwartzman K; Oxlade O; Klein MB; Greenaway C
    PLoS One; 2013; 8(10):e78548. PubMed ID: 24205255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.
    Suijkerbuijk AWM; van Hoek AJ; Koopsen J; de Man RA; Mangen MJ; de Melker HE; Polder JJ; de Wit GA; Veldhuijzen IK
    PLoS One; 2018; 13(11):e0207037. PubMed ID: 30408079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
    Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
    Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
    Wong WW; Hicks LK; Tu HA; Pritchard KI; Krahn MD; Feld JJ; Chan KK
    Breast Cancer Res Treat; 2015 Jun; 151(3):639-52. PubMed ID: 25962692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
    Liu S; Watcha D; Holodniy M; Goldhaber-Fiebert JD
    Ann Intern Med; 2014 Oct; 161(8):546-53. PubMed ID: 25329202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 13. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.
    Bloom BS; Hillman AL; Fendrick AM; Schwartz JS
    Ann Intern Med; 1993 Feb; 118(4):298-306. PubMed ID: 8420448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
    Juusola JL; Brandeau ML; Owens DK; Bendavid E
    Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis.
    Mokhtari AM; Barouni M; Moghadami M; Hassanzadeh J; Dewey RS; Mirahmadizadeh A
    Hum Vaccin Immunother; 2021 Jun; 17(6):1825-1833. PubMed ID: 33734949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
    Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
    Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
    Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
    J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Rosenthal EM; Hall EW; Rosenberg ES; Harris A; Nelson NP; Schillie S
    Vaccine; 2020 Dec; 38(51):8206-8215. PubMed ID: 33160756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.